Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187.

Reeves KJ, Hurrell JE, Cecchini M, van der Pluijm G, Down JM, Eaton CL, Hamdy F, Clement-Lacroix P, Brown NJ.

Int J Cancer. 2015 Apr 1;136(7):1731-40. doi: 10.1002/ijc.29165. Epub 2014 Sep 4.

2.

Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.

van der Horst G, van den Hoogen C, Buijs JT, Cheung H, Bloys H, Pelger RC, Lorenzon G, Heckmann B, Feyen J, Pujuguet P, Blanque R, Clément-Lacroix P, van der Pluijm G.

Neoplasia. 2011 Jun;13(6):516-25.

3.

Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.

Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML.

J Natl Cancer Inst. 2002 Jan 2;94(1):17-25.

PMID:
11773278
4.

Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine.

Glinskii OV, Sud S, Mossine VV, Mawhinney TP, Anthony DC, Glinsky GV, Pienta KJ, Glinsky VV.

Neoplasia. 2012 Jan;14(1):65-73.

5.

Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.

Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ, Cher ML.

Cancer Res. 1999 Apr 15;59(8):1987-93.

6.

An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.

Xu S, Zhang Z, Ogawa O, Yoshikawa T, Sakamoto H, Shibasaki N, Goto T, Wang L, Terada N.

Cell Biochem Biophys. 2014 Sep;70(1):521-7. doi: 10.1007/s12013-014-9951-2.

PMID:
24744183
8.

Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.

Angelucci A, Gravina GL, Rucci N, Millimaggi D, Festuccia C, Muzi P, Teti A, Vicentini C, Bologna M.

Endocr Relat Cancer. 2006 Mar;13(1):197-210.

PMID:
16601288
9.

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

Dai J, Zhang H, Karatsinides A, Keller JM, Kozloff KM, Aftab DT, Schimmoller F, Keller ET.

Clin Cancer Res. 2014 Feb 1;20(3):617-30. doi: 10.1158/1078-0432.CCR-13-0839. Epub 2013 Oct 4.

10.

Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein.

Li Y, Che M, Bhagat S, Ellis KL, Kucuk O, Doerge DR, Abrams J, Cher ML, Sarkar FH.

Neoplasia. 2004 Jul-Aug;6(4):354-63.

11.

Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.

Muñoz-Moreno L, Arenas MI, Schally AV, Fernández-Martínez AB, Zarka E, González-Santander M, Carmena MJ, Vacas E, Prieto JC, Bajo AM.

Int J Cancer. 2013 Feb 15;132(4):755-65. doi: 10.1002/ijc.27716. Epub 2012 Jul 27.

12.

Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.

Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR.

Bone. 2006 Feb;38(2):154-66. Epub 2005 Aug 26.

PMID:
16126463
13.

Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.

Singh AS, Macpherson GR, Price DK, Schimel D, Figg WD.

Oncol Rep. 2006 Mar;15(3):519-24.

PMID:
16465406
14.

Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.

Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR.

J Bone Miner Res. 2005 Dec;20(12):2189-99. Epub 2005 Aug 1.

15.

SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis.

Rabbani SA, Valentino ML, Arakelian A, Ali S, Boschelli F.

Mol Cancer Ther. 2010 May;9(5):1147-57. doi: 10.1158/1535-7163.MCT-09-0962. Epub 2010 Apr 27.

16.

N'-Formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide as a potential anti-tumour agent for prostate cancer in experimental studies.

Rodrigues JR, Charris J, Camacho J, Barazarte A, Gamboa N, Nitzsche B, Höpfner M, Lein M, Jung K, Abramjuk C.

J Pharm Pharmacol. 2013 Mar;65(3):411-22. doi: 10.1111/j.2042-7158.2012.01607.x. Epub 2012 Nov 16.

PMID:
23356850
17.

Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.

Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Gröne HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE.

Clin Cancer Res. 2005 Sep 1;11(17):6270-9.

18.

The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo.

Lin E, Wang Q, Swenson S, Jadvar H, Groshen S, Ye W, Markland FS, Pinski J.

Prostate. 2010 Sep 1;70(12):1359-70. doi: 10.1002/pros.21173.

PMID:
20623636
19.

Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.

Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, Tallant EA, Gallagher PE.

Prostate. 2013 Jan;73(1):71-82. doi: 10.1002/pros.22542. Epub 2012 May 29.

20.

Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.

Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A.

Cancer Res. 2003 May 1;63(9):2096-102.

Supplemental Content

Support Center